These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9486581

  • 1. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
    Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P.
    Cancer; 1998 Mar 01; 82(5):909-17. PubMed ID: 9486581
    [Abstract] [Full Text] [Related]

  • 2. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.
    Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Aug 01; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV.
    Pancreas; 1993 Jan 28; 8(1):88-97. PubMed ID: 8093555
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
    Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G.
    Proc Natl Acad Sci U S A; 1997 May 27; 94(11):5810-3. PubMed ID: 9159156
    [Abstract] [Full Text] [Related]

  • 10. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 27; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 11. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K.
    Int J Cancer; 1993 Dec 02; 55(6):963-7. PubMed ID: 7902829
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S, Miller G, Schally AV.
    Cancer Res; 1991 Nov 01; 51(21):6006-9. PubMed ID: 1682040
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T.
    Acta Oncol; 1994 Nov 01; 33(6):693-701. PubMed ID: 7946450
    [Abstract] [Full Text] [Related]

  • 16. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E.
    J Cancer Res Clin Oncol; 1999 Nov 01; 125(8-9):444-52. PubMed ID: 10480336
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B.
    Cancer Res; 1991 Nov 01; 51(21):5980-6. PubMed ID: 1682039
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1987 Oct 01; 84(20):7275-9. PubMed ID: 2890164
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K.
    Cancer Res; 1994 Nov 15; 54(22):5895-901. PubMed ID: 7954420
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.